PL3810128T3 - Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek - Google Patents
Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białekInfo
- Publication number
- PL3810128T3 PL3810128T3 PL19730826.5T PL19730826T PL3810128T3 PL 3810128 T3 PL3810128 T3 PL 3810128T3 PL 19730826 T PL19730826 T PL 19730826T PL 3810128 T3 PL3810128 T3 PL 3810128T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- treating
- preventing protein
- aggregation diseases
- aggregation
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382439 | 2018-06-19 | ||
| PCT/EP2019/066271 WO2019243453A1 (en) | 2018-06-19 | 2019-06-19 | Compositions for treating and/or preventing protein-aggregation diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3810128T3 true PL3810128T3 (pl) | 2023-01-30 |
Family
ID=62716030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19730826.5T PL3810128T3 (pl) | 2018-06-19 | 2019-06-19 | Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210251953A1 (pl) |
| EP (2) | EP3810128B1 (pl) |
| JP (2) | JP2021528442A (pl) |
| CN (1) | CN112601521A (pl) |
| AU (1) | AU2019291061A1 (pl) |
| BR (1) | BR112020026066A2 (pl) |
| CA (1) | CA3103834A1 (pl) |
| DK (1) | DK3810128T3 (pl) |
| ES (1) | ES2931815T3 (pl) |
| MX (1) | MX2020014070A (pl) |
| PL (1) | PL3810128T3 (pl) |
| PT (1) | PT3810128T (pl) |
| WO (1) | WO2019243453A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3988096A1 (en) | 2020-10-26 | 2022-04-27 | Universidad Pablo de Olavide OTRI | Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases |
| CN112552272B (zh) * | 2020-12-22 | 2023-06-27 | 四川大学 | 香豆素类化合物及其制备方法和应用、药物组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9603325D0 (en) | 1996-02-16 | 1996-04-17 | Imperial College | A compound |
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| JP4320089B2 (ja) * | 1999-07-06 | 2009-08-26 | あすか製薬株式会社 | フェニルスルファメート誘導体 |
| EP2140868A1 (en) * | 2000-03-03 | 2010-01-06 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| GB0511190D0 (en) * | 2005-06-01 | 2005-07-06 | Sterix Ltd | Use |
| ES2514140B1 (es) * | 2013-03-26 | 2015-08-03 | Universidad Pablo De Olavide | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento |
| KR20170092634A (ko) * | 2014-12-05 | 2017-08-11 | 에이엔2에이치 디스커버리 리미티드 | 파킨 리가제 활성화 방법 및 조성물 |
| MX2018005352A (es) | 2015-10-30 | 2018-08-14 | Ultragenyx Pharmaceutical Inc | Metodos y composiciones para el tratamiento de amiloidosis. |
| US10780094B2 (en) * | 2016-07-22 | 2020-09-22 | New York University | Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders |
-
2019
- 2019-06-19 CA CA3103834A patent/CA3103834A1/en active Pending
- 2019-06-19 BR BR112020026066-5A patent/BR112020026066A2/pt unknown
- 2019-06-19 PT PT197308265T patent/PT3810128T/pt unknown
- 2019-06-19 MX MX2020014070A patent/MX2020014070A/es unknown
- 2019-06-19 WO PCT/EP2019/066271 patent/WO2019243453A1/en unknown
- 2019-06-19 DK DK19730826.5T patent/DK3810128T3/da active
- 2019-06-19 CN CN201980054686.3A patent/CN112601521A/zh active Pending
- 2019-06-19 AU AU2019291061A patent/AU2019291061A1/en active Pending
- 2019-06-19 ES ES19730826T patent/ES2931815T3/es active Active
- 2019-06-19 US US17/253,378 patent/US20210251953A1/en active Pending
- 2019-06-19 JP JP2020571600A patent/JP2021528442A/ja active Pending
- 2019-06-19 EP EP19730826.5A patent/EP3810128B1/en active Active
- 2019-06-19 PL PL19730826.5T patent/PL3810128T3/pl unknown
- 2019-06-19 EP EP22186334.3A patent/EP4094754A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025631A patent/JP2024059803A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021528442A (ja) | 2021-10-21 |
| PT3810128T (pt) | 2022-11-09 |
| US20210251953A1 (en) | 2021-08-19 |
| WO2019243453A1 (en) | 2019-12-26 |
| AU2019291061A1 (en) | 2021-02-04 |
| JP2024059803A (ja) | 2024-05-01 |
| EP3810128A1 (en) | 2021-04-28 |
| CN112601521A (zh) | 2021-04-02 |
| BR112020026066A2 (pt) | 2021-03-23 |
| EP3810128B1 (en) | 2022-08-03 |
| ES2931815T3 (es) | 2023-01-02 |
| MX2020014070A (es) | 2021-05-27 |
| EP4094754A1 (en) | 2022-11-30 |
| CA3103834A1 (en) | 2019-12-26 |
| DK3810128T3 (da) | 2022-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202011080QA (en) | Methods and compositions for treating cancer | |
| IL273959A (en) | Methods and preparations for the treatment of rare diseases | |
| IL276808A (en) | Preparations and methods for the treatment of cancer | |
| EP3634424A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | |
| EP3826666A4 (en) | COMPOSITIONS AND METHODS OF TREATING DISEASES ASSOCIATED WITH NRP2 | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| IL287796A (en) | Preparations and methods for the treatment of diseases mediated by ATPase | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| ZA202100703B (en) | Compositions and methods for treating inflammasome related diseases or conditions | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| SG11202012070YA (en) | Methods and compositions for preventing or treating tissue calcification | |
| EP3818085A4 (en) | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| EP3609525A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF INTESTINAL PERMEABILITY DISORDERS | |
| IL275767A (en) | Compositions and methods for treating metabolic diseases | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| EP3768095A4 (en) | Compositions and methods for treating diarrheal diseases | |
| GB202001422D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
| PT3810128T (pt) | Composições para tratar e/ou prevenir doenças de agregação de proteinas | |
| ZA202101360B (en) | Compositions and methods for treating the eye | |
| ZA202101361B (en) | Compositions and methods for treating the eye |